Update on Treatments for the Non-Motor Symptoms of Parkinson’s Disease – an Evidence-Based Medicine Review

References
90. Webster P. Pimavanserin evaluated by the FDA. Lancet 2018;391:1762.
91. (FDA) UFaDA. FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson’s disease psychosis. 2018; https://www.fda.gov/Drugs/DrugSafety/ucm621160.htm Last accessed: 8 October 2018.


